Physician profile
Ross Simon
NPI 1548655079
$6,033.45
in general payments reported to CMS, 2019-2025
37 companies · $920 in 2025
The $920 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $381 · 2020: $326 · 2021: $930 · 2022: $845 · 2023: $1,983 · 2024: $649 · 2025: $920.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,699 · Travel and Lodging: $852.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,699.35 |
| Travel and Lodging | $852.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $1,109.35 | 2019-2025 | Titan, Speedicath |
| Axonics, INC. | $1,020.56 | 2021-2024 | Axonics, Bulkamid |
| Intuitive Surgical, INC. | $933.46 | 2022-2025 | Da Vinci Surgical System |
| Boston Scientific Corporation | $546.38 | 2020-2025 | Axonics, Spaceoar Vue System - 10ml, Ams 700 |
| Endo Pharmaceuticals INC. | $237.11 | 2020-2024 | Xiaflex, Aveed, Edex |
| Karl Storz Endoscopy-America | $203.07 | 2022 | |
| Medtronic USA, INC. | $190.48 | 2019-2020 | |
| Janssen Biotech, INC. | $186.38 | 2020-2025 | Erleada |
| Procept Biorobotics Corporation | $180.93 | 2023-2025 | Aquabeam Robotic System, Aquabeam System |
| Abbvie INC. | $159.77 | 2022-2025 | Botox |
| Dendreon Pharmaceuticals LLC | $130.06 | 2021-2024 | Provenge |
| Endo USA, INC. | $123.74 | 2024-2025 | Xiaflex, Aveed, Edex |
| Astellas Pharma US INC | $114.17 | 2021-2025 | Xtandi |
| Axogen | $89.67 | 2025 | |
| Medtronic, INC. | $86.61 | 2025 | Interstim |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $72.36 | 2021-2023 | |
| Telix Pharmaceuticals | $51.79 | 2023-2025 | Illuccix |
| Sumitomo Pharma America, INC. | $49.18 | 2023-2025 | Gemtesa, Orgovyx |
| Calyxo, INC. | $46.33 | 2025 | Cvac Aspiration System |
| Merck Sharp & Dohme LLC | $44.04 | 2025 | Keytruda |
| Angiodynamics, INC. | $42.73 | 2022-2025 | Nanoknife |
| Teleflex LLC | $42.25 | 2023-2024 | Urolift |
| Allergan, INC. | $36.76 | 2020-2022 | |
| Menarini Silicon Biosystems, INC. | $36.12 | 2023 | Cellsearch |
| Tolmar, INC. | $33.40 | 2025 | Eligard |
| Baxter Healthcare | $30.90 | 2023 | Floseal |
| Novartis Pharmaceuticals Corporation | $30.44 | 2025 | |
| Accord Healthcare, INC. | $25.96 | 2023 | |
| Lumenis, INC | $25.30 | 2021 | |
| Verity Pharmaceuticals INC. | $24.58 | 2025 | Tlando |
| Travere Therapeutics, INC. | $21.77 | 2021 | |
| Urovant Sciences INC | $20.44 | 2022 | |
| Tolmar Pharmaceuticals, INC. | $19.09 | 2021 | |
| Caldera Medical, INC | $18.76 | 2025 | |
| Pfizer INC. | $17.65 | 2024 | |
| Edap Technomed INC | $16.66 | 2023 | |
| Astrazeneca Pharmaceuticals Lp | $15.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ross Simon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.